U.S. markets closed
  • S&P 500

    +39.95 (+1.06%)
  • Dow 30

    +321.83 (+1.05%)
  • Nasdaq

    +99.11 (+0.90%)
  • Russell 2000

    +19.77 (+1.16%)
  • Crude Oil

    +2.70 (+2.55%)
  • Gold

    +5.60 (+0.31%)
  • Silver

    -0.50 (-2.44%)

    -0.0057 (-0.54%)
  • 10-Yr Bond

    -0.0830 (-2.79%)

    -0.0072 (-0.59%)

    -0.5530 (-0.41%)

    -91.75 (-0.48%)
  • CMC Crypto 200

    +0.70 (+0.17%)
  • FTSE 100

    -0.63 (-0.01%)
  • Nikkei 225

    -457.42 (-1.73%)

Top Research Reports for Novo Nordisk, AMD & Netflix

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Tuesday, April 26, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>

Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+53% vs. +28.4%). Novo Nordisk’s marketed diabetes drug, Ozempic, is off to a solid start. The launch of Rybelsus also looks impressive. Yearly growth is driven by all geographical areas. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum.

The Zacks analyst believes that Label expansion of these existing drugs is expected to further boost sales. However, lower realized prices in the Unites States, loss of exclusivity for products and stiff competition are affecting sales. Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy has hurt the stock. The patent expiry on some of the products in Novo Nordisk’s portfolio is concerning too.

(You can read the full research report on Novo Nordisk here >>>)

Advanced Micro Devices shares have gained +2.2% over the past year against the Zacks Electronics - Semiconductors industry’s gain of +4.4%. The company is benefiting from strong demand of its Ryzen and EPYC server processors, courtesy of the increasing proliferation of Artificial Intelligence (AI) and Machine Learning (ML) in industries like cloud, gaming and data center. The growing clout of 7 nanometer (nm) products in the data center vertical, driven by work-from-home and online learning trends, is a key catalyst. AMD provided strong 2022 guidance for revenues backed by robust growth across all businesses.

Higher server and client processor revenues are likely to lead to a sequential increase. The Xilinx and Pensando acquisitions will bolster AMD's data center business. Alliances with Amazon, Microsoft, Baidu and JD.com are likely to augment business prospects. However, stiff competition from NVIDIA and Intel remains a concern.

(You can read the full research report on Advanced Micro Devices here >>>)

Netflix shares have declined -60.0% over the past year against the Zacks Broadcast Radio and Television industry’s decline of -43.0%. The company is suffering from stiff competition in the streaming space like Apple, Amazon prime video, HBO Max, Disney+, Peacock, Paramount+ and TikTok. The company’s leveraged balance sheet and higher streaming obligation are major concerns. Stiff competition, the unfavorable impact of account sharing, sluggish economic growth, increasing inflation, the Russia-Ukraine conflict and some continued disruptions from COVID-19.

However, Netflix is expected to continue to dominate the streaming space, courtesy of its diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content.

(You can read the full research report on Netflix here >>>)

Other noteworthy reports we are featuring today include Merck & Co., Inc. (MRK), Merck & Co., Inc. (MRK), and Marsh & McLennan Companies, Inc. (MMC).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Novo Nordisk's (NVO) Diabetes Drugs Aid Growth Amid Rivalry

Robust Product Portfolio & Partnerships Aid AMD's Prospects

Weak Content Slate & Stiff Competition Hurts Netflix (NFLX)

Featured Reports

Key Drugs & Animal Health Unit Drive Merck's (MRK) Sales
Merck's (MRK) drugs like Keytruda, Lynparza and Bridion have been driving sales. The Zacks analyst believes that Animal health and vaccine products remain core growth drivers.

Strategic Buyouts Aid Morgan Stanley (MS), High Costs Ails
Per the Zacks analyst, inorganic expansion plans to focus on less capital markets dependent businesses and solid balance sheet aid Morgan Stanley. Yet, rising operating costs remain a major concern.

Per the Zacks analyst, a number of acquisitions help Marsh & McLennan
Per the Zacks analyst, a number of acquisitions help Marsh & McLennan expand geographically, and diversify its portfolio. Yet, escalating expenses continue to weigh down margins.

Focus on Permian Basin, Cost Management Aid Occidental (OXY)
Per the Zacks analyst Occidental's efficient cost management and expansion of its operation Permian Basin through acquisition of Anadarko will drive its performance over the long run.

Solid User Growth & Premium Content Demand Aids Snap (SNAP)
Per the Zacks analyst, Snap benefits from an improving user growth driven by strong adoption of Augmented Reality (AR) Lenses and demand for premium Discover content and Shows.

Solid Balance Sheet Supports BNY Mellon (BK) Amid Low Rates
Per the Zacks analyst, solid balance sheet and efforts to improve efficiency through cost control will aid BNY Mellon. Despite the expected rate hikes, relatively low rates might hurt interest income.

VeriSign (VRSN) Gains on Higher Demand for Domain Names
Per the Zacks analyst, VeriSign has been gaining from growth in .com and .net domain name registrations. However, surging expenses related to cybersecurity and infrastructure spending is a concern.

New Upgrades

Suncor (SU) to Benefit from Strong Liquidity Position
The Zacks analyst likes Suncor's strong financial position. The company has near-term debt maturities of a mere C$1.8 billion and sits on more than C$4 billion in total liquidity.

Pool Corp (POOL) Rides on Capacity Creation Initiatives
Per the Zacks analyst, Pool Corp is likely to have benefitted from solid demand, healthy contractor backlogs and capacity-creation initiatives. Also, focus on expansions through acquisitions bode well

Solid Order Levels, Product Innovation Aid Manitowoc (MTW)
Per the Zacks Analyst, solid order levels, product innovation as well as focus on cost controls and increasing productivity are likely to drive Manitowoc's results.

New Downgrades

Soft Hard Seltzer to Ail Boston Beer's (SAM) Performance
Per the Zacks analyst, Boston Beer has been reeling under slowed growth trends in hard seltzer for some time now. Q1 hard seltzer sales declined 3% in measured off-premise channels.

Low Paper-Related Demand & High Debt Weaken Xerox (XRX)
The Zacks analyst is pessimistic about Xerox grappling with decreased demand for paper-related systems and products. Also, low current ratio is worrisome.

High Cost & Traffic Woes Likely to Hurt Cracker Barrel (CBRL)
Per the Zacks analyst, Cracker Barrel is likely to be impacted by higher labor costs due to increased wages and dismal traffic. The company is apprehensive regarding incurring inflationary costs.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Morgan Stanley (MS) : Free Stock Analysis Report
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
Novo Nordisk AS (NVO) : Free Stock Analysis Report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Netflix, Inc. (NFLX) : Free Stock Analysis Report
Marsh & McLennan Companies, Inc. (MMC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research